Dolutegravir Resistance in Malawi’s National HIV Treatment Program-Reference-Cited by-同舟云学术

Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Published:2022-04-05 Issue:5 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

van Oosterhout Joep J¹²,Chipungu Chifundo¹,Nkhoma Lyse³,Kanise Hope¹,Hosseinipour Mina C⁴,Sagno Jean Babtiste⁵,Simon Katherine⁶⁷,Cox Carrie⁶⁷,Hoffman Risa²,Steegen Kim⁸⁹,Matola Bilaal W¹⁰,Phiri Sam¹¹⁰,Jahn Andreas¹¹,Nyirenda Rose¹¹,Heller Tom³

Affiliation:

1. Partners in Hope, Lilongwe, Malawi

2. Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA

3. The Lighthouse Trust, Lilongwe, Malawi

4. University of North Carolina Project Malawi, Lilongwe, Malawi

5. DREAM, Communion of St. Egidio, Blantyre, Malawi

6. Baylor College of Medicine Children’s Foundation-Malawi, Lilongwe, Malawi

7. Baylor International Pediatric AIDS Initiative, Houston, Texas, USA

8. Department of Haematology & Molecular Medicine, National Health Laboratory Service, Johannesburg, South Africa

9. Department of Haematology & Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa

10. Department of Public Health and Family Medicine, Kamuzu University of Health Sciences, Lilongwe, Malawi

11. Department of HIV-AIDS, Ministry of Health, Lilongwe, Malawi

Abstract

Abstract Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.

Funder

United States Agency for International Development

Centers for Disease Control and Prevention

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac148/43289001/ofac148.pdf

Reference19 articles.

1. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.;Inzaule;Lancet Infect Dis,2019

2. Dolutegravir plus two different prodrugs of tenofovir to treat HIV.;Venter;N Engl J Med,2019